

Meningococcal Vaccines Work Group Update

Lorry Rubin, M.D.

**Chair, Meningococcal Work Group
Advisory Committee on Immunization Practices**

October 30, 2014

Work Group Members

ACIP Members

Lorry Rubin (Chair)
Doug Campos-Outcalt

***Ex Officio* Members**

Lucia Lee (FDA)
Meghan Ferris(FDA)

Work Group Lead

Jessica MacNeil (CDC/NCIRD)
Manisha Patel (CDC/NCIRD)

Liaison and Other Representatives

Mike Brady (AAP)
Susan Even (ACHA)
Rachel Herlihy (IAC)
Nneka Holder (SAHM)
Martin Luta (CSTE)
Jeffrey Moore (AAFP)
William Schaffner (NFID)
Bill Atkinson
Carol Baker
Richard Clover
Scott Kapoor
Paul McKinney
Cody Meissner
Paul Offit
Georges Peter
David Stephens

Serogroup B Meningococcal (MenB) Vaccines

- ❑ **rLP2086 or Trumenba[®] (Pfizer) was licensed in the US for persons 10-25 years of age on October 29, 2014**
- ❑ **4CMenB, or Bexsero[®] (Novartis) currently under FDA review for persons 10-25 years of age**
 - Novartis action date March 24, 2015
- ❑ **MenB vaccines are distinct from MenACWY vaccines because they are based on immunity to proteins rather than capsular polysaccharides**

Use of MenB Vaccine for Outbreak Response

- ❑ In 2013, 2 universities experienced outbreaks of serogroup B meningococcal disease with a combined 13 cases and one death reported
- ❑ Vaccination campaigns were conducted at both universities in response to the outbreaks using an investigational MenB vaccine (Novartis Vaccines) obtained through an expanded access Investigational New Drug (IND) application sponsored by CDC
- ❑ Guidance for use of serogroup B vaccines in institutional outbreaks has been developed and is available at:
<http://www.cdc.gov/meningococcal/downloads/interim-guidance.pdf>

Today's Session

- ❑ **4CMenB (Bexsero[®]) (Jim Wassil, Novartis)**
- ❑ **Bivalent rLP2086 (Trumenba[®]) (Laura York, Pfizer)**
- ❑ **Epidemiology of Serogroup B Meningococcal Disease in the United States (Jessica MacNeil, CDC)**
- ❑ **Overview of Serogroup B Meningococcal Vaccines and Considerations for Use (Manisha Patel, CDC)**
- ❑ **No votes will be taken**

Timeline

- ❑ **February 2015 ACIP Meeting**
 - Proposed recommendations for use of serogroup B vaccines in persons ≥ 10 years of age with high-risk medical conditions, laboratory workers, and outbreaks
- ❑ **ACIP Meningococcal Vaccines Work Group will review data on MenB vaccines as it becomes available and will continue discussions on use and potential impact of these vaccines**
- ❑ **Updated outbreak control guidelines will be developed which address outbreaks due to all serogroups**